Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the US Department of Defense …
BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
[HTML][HTML] Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department …
K Gupta, J Trocio, A Keshishian, Q Zhang… - Journal of Managed …, 2018 - ncbi.nlm.nih.gov
BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
[引用][C] Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department of …
K Gupta, J Trocio, A Keshishian, Q Zhang… - Journal of Managed …, 2018 - cir.nii.ac.jp
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants
in Nonvalvular Atrial Fibrillation Patients in the US Department of Defense Population | CiNii …
in Nonvalvular Atrial Fibrillation Patients in the US Department of Defense Population | CiNii …
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department of …
K Gupta, J Trocio, A Keshishian, Q Zhang… - Journal of Managed …, 2018 - europepmc.org
Background The ARISTOTLE trial demonstrated that apixaban had significantly lower rates
of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department of …
K Gupta, J Trocio, A Keshishian… - … of managed care …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The ARISTOTLE trial demonstrated that apixaban had significantly lower rates
of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department of …
K Gupta, J Trocio, A Keshishian, Q Zhang… - WHAT DO WE REALLY …, 2018 - jmcp.org
ABSTRACT BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had
significantly lower rates of stroke/systemic embolism (SE) and major bleeding than warfarin; …
significantly lower rates of stroke/systemic embolism (SE) and major bleeding than warfarin; …